BioSpace News Archive

EVERSANA today announced it has completed its acquisition of Intouch Group®, a full-service global agency network serving the pharmaceutical industry.

GeneCentric Therapeutics announced today the completion of its Piedmont Study, conducted in collaboration with Atrium Health Levine Cancer Institute.

EXUMA Biotech, Corp., a clinical-stage biotechnology company discovering and developing cell and gene therapies and delivery solutions for liquid and solid tumors, today announced the completion of a $41 million Series B2 financing.

DermBiont announced today that it has raised a $28 million Series A2 financing in parallel with the acquisition of clinical-stage biotechnology company Chromaderm.

BioSig Technologies, Inc., a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, announced that it appointed Access Strategy Partners, Inc. to advise on the next phase of the commercial roll-out.

Abbott will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 11, 2022. Robert B. Ford, chairman and chief executive officer, will present at 8 a.m. Central time.

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), today announced that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for QINLOCK® (ripretinib).

CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), today announced that it has received a positive response from the U.S. Food and Drug Administration (“FDA”) to conduct a Phase 3, randomized, double blind, placebo controlled trial to evaluate the efficacy and safety of leronlimab in combination with standard of care for critically ill patients with COVID-19 pneumonia with need for Invasive Mechanical Ventilation (“IMV”) or Extracorporeal Membrane Oxygenation (“ECMO”).

Cassava Sciences, Inc., a biotechnology company, has been informed by Neuroscience journal there is no evidence to support claims of data manipulation in a 2005 paper1 authored by the Company and its scientific collaborators.

Mezzion Pharma Co., Ltd. (Mezzion Pharma) announces that new data from its Phase 3 efficacy and safety trial (FUEL Trial) and its open label extension trial (FUEL OLE Trial) that concerns the treatment of a very large subgroup of patients with congenital single ventricle heart disease (SVHD) who have Fontan physiology was presented to the U.S. Food and Drug Administration (FDA) in a Type C meeting held on Thursday, December 16, 2021.